S. Wittebol

Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab

Michael S. van der Veer, Michel de Weers, Berris van Kessel et al. · Haematologica · 2010 · 217 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Predominance of functional multidrug resistance (MDR-1) phenotype in CD34+ acute myeloid leukemia cells

PA te Boekhorst, K. De Leeuw, M. Schoester et al. · Blood · 1993 · 157 citations · Full text

Medicine, Cancer Biology, Oncology +12

Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma

H M Lokhorst, Ingo GH Schmidt-Wolf, Pieter Sonneveld et al. · Haematologica · 2007 · 142 citations · Full text

Medicine, Oncology, Pharmacology +14

Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial

Christoph Scheid, P. Sonneveld, Ingo Schmidt‐Wolf et al. · Haematologica · 2013 · 127 citations · Full text

Medicine, Hematology, Pharmacotherapy +13

Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first‐line treatment in untreated multiple myeloma

Christine M. Segeren, Pieter Sonneveld, Bronno van der Holt et al. · British Journal of Haematology · 1999 · 98 citations · Full text

Medicine, Hematology, Oncology +16